Cargando…

Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten(®)

OBJECTIVES: Vulvovaginal candidiasis is common in women, causing discomfort and negatively impacting quality of life. Canesten(®) is an established over-the-counter brand. Its clotrimazole/fluconazole-based products, available in a variety of different formulations, have demonstrated efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lei, De Salvo, Raffaella, Ehret, Andreas, Young, Kimberley, Trapp, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969009/
https://www.ncbi.nlm.nih.gov/pubmed/35371482
http://dx.doi.org/10.1177/20503121221085437
_version_ 1784679169037172736
author Zhang, Lei
De Salvo, Raffaella
Ehret, Andreas
Young, Kimberley
Trapp, Sonja
author_facet Zhang, Lei
De Salvo, Raffaella
Ehret, Andreas
Young, Kimberley
Trapp, Sonja
author_sort Zhang, Lei
collection PubMed
description OBJECTIVES: Vulvovaginal candidiasis is common in women, causing discomfort and negatively impacting quality of life. Canesten(®) is an established over-the-counter brand. Its clotrimazole/fluconazole-based products, available in a variety of different formulations, have demonstrated efficacy and safety in the treatment of women with thrush/vaginal yeast infection in randomized trials. This real-world evidence study, conducted in the United Kingdom and Canada, aimed to provide consumer-important information on the benefits of Canesten, collecting retrospective information from consumers about their recent experience with the product. METHODS: Eligible participants were female, aged 18–60 years, and had experienced at least one episode of vaginal thrush (United Kingdom)/vaginal yeast infection (Canada) during the previous 6 months for which they had used at least one of the six Canesten products. Participants completed an online questionnaire eliciting information on the speed of onset of symptom relief, impact on quality of life, and product attributes/satisfaction. RESULTS: Over 90% of respondents reported improvements in symptoms and quality of life after starting treatment with a Canesten product. Improvements in symptoms within 4 h of the first time of use were perceived by 42% of consumers; 76%–88% reported symptomatic relief within 1 day. The perceived general speed of onset of symptomatic relief with a Canesten oral product (1–2 days) was slightly longer than that with a Canesten topical/intra-vaginal product (⩽1 day). Most users of Canesten single (90%) and dual product treatments (95%) reported that the products started to work from the first application. Women experiencing both internal and external symptoms of thrush/vaginal yeast infection reported Canesten dual product formulations to provide faster symptomatic relief than single product treatments. Over 90% of respondents were satisfied with their use of a Canesten product. CONCLUSION: Canesten was found by consumers to offer rapid relief of the symptoms of thrush/vaginal yeast infection with improvements in quality of life. Consumer satisfaction was high.
format Online
Article
Text
id pubmed-8969009
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89690092022-04-01 Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten(®) Zhang, Lei De Salvo, Raffaella Ehret, Andreas Young, Kimberley Trapp, Sonja SAGE Open Med Original Research Article OBJECTIVES: Vulvovaginal candidiasis is common in women, causing discomfort and negatively impacting quality of life. Canesten(®) is an established over-the-counter brand. Its clotrimazole/fluconazole-based products, available in a variety of different formulations, have demonstrated efficacy and safety in the treatment of women with thrush/vaginal yeast infection in randomized trials. This real-world evidence study, conducted in the United Kingdom and Canada, aimed to provide consumer-important information on the benefits of Canesten, collecting retrospective information from consumers about their recent experience with the product. METHODS: Eligible participants were female, aged 18–60 years, and had experienced at least one episode of vaginal thrush (United Kingdom)/vaginal yeast infection (Canada) during the previous 6 months for which they had used at least one of the six Canesten products. Participants completed an online questionnaire eliciting information on the speed of onset of symptom relief, impact on quality of life, and product attributes/satisfaction. RESULTS: Over 90% of respondents reported improvements in symptoms and quality of life after starting treatment with a Canesten product. Improvements in symptoms within 4 h of the first time of use were perceived by 42% of consumers; 76%–88% reported symptomatic relief within 1 day. The perceived general speed of onset of symptomatic relief with a Canesten oral product (1–2 days) was slightly longer than that with a Canesten topical/intra-vaginal product (⩽1 day). Most users of Canesten single (90%) and dual product treatments (95%) reported that the products started to work from the first application. Women experiencing both internal and external symptoms of thrush/vaginal yeast infection reported Canesten dual product formulations to provide faster symptomatic relief than single product treatments. Over 90% of respondents were satisfied with their use of a Canesten product. CONCLUSION: Canesten was found by consumers to offer rapid relief of the symptoms of thrush/vaginal yeast infection with improvements in quality of life. Consumer satisfaction was high. SAGE Publications 2022-03-28 /pmc/articles/PMC8969009/ /pubmed/35371482 http://dx.doi.org/10.1177/20503121221085437 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Zhang, Lei
De Salvo, Raffaella
Ehret, Andreas
Young, Kimberley
Trapp, Sonja
Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten(®)
title Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten(®)
title_full Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten(®)
title_fullStr Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten(®)
title_full_unstemmed Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten(®)
title_short Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten(®)
title_sort vulvovaginal candidiasis: a real-world evidence study of the perceived benefits of canesten(®)
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969009/
https://www.ncbi.nlm.nih.gov/pubmed/35371482
http://dx.doi.org/10.1177/20503121221085437
work_keys_str_mv AT zhanglei vulvovaginalcandidiasisarealworldevidencestudyoftheperceivedbenefitsofcanesten
AT desalvoraffaella vulvovaginalcandidiasisarealworldevidencestudyoftheperceivedbenefitsofcanesten
AT ehretandreas vulvovaginalcandidiasisarealworldevidencestudyoftheperceivedbenefitsofcanesten
AT youngkimberley vulvovaginalcandidiasisarealworldevidencestudyoftheperceivedbenefitsofcanesten
AT trappsonja vulvovaginalcandidiasisarealworldevidencestudyoftheperceivedbenefitsofcanesten